APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

This study tests a drug called APG-2449 (alone or combined with liposomal doxorubicin chemotherapy) in patients with ovarian cancer that has stopped responding to platinum-based chemotherapy (platinum-resistant), or in patients with certain advanced solid tumors driven by specific gene fusions. **You may be eligible if...** - You have platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer (for Part B) - You have advanced solid tumors with ALK or ROS1 gene fusions (for Part A, any gender) - You have at least one measurable tumor - You are physically functional (ECOG 0–1) - You are not pregnant or breastfeeding - Your organ function and blood counts are within acceptable ranges **You may NOT be eligible if...** - You had major surgery or trauma in the past 28 days - You received recent anti-cancer treatment - You have previously been treated with a FAK inhibitor drug - You have active brain metastases - You have serious heart or gastrointestinal disease, or uncontrolled fluid around the lungs or abdomen - You had another cancer within the past 3 years Talk to your doctor to see if this trial is right for you.